genedrive Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

James Cheek

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	5.7yrs

Recent management updates

Recent updates

CEO

James Cheek (56 yo)

less than a year

Tenure

Mr. James Cheek is Chief Executive Officer & Director of genedrive plc from September 11, 2023. He has extensive commercial and operational experience. He has experience working at Cepheid, Beckman Coulter...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Russell Shaw	CFO, Secretary & Director	2yrs	UK£158.08k	no data
James Cheek	CEO & Director	less than a year	no data	no data
Gino Miele	Chief Scientific Officer & Executive Director	less than a year	no data	no data

0.6yrs

Average Tenure

53yo

Average Age

Experienced Management: GDR's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Russell Shaw	CFO, Secretary & Director	no data	UK£158.08k	no data
James Cheek	CEO & Director	less than a year	no data	no data
Gino Miele	Chief Scientific Officer & Executive Director	less than a year	no data	no data
Ian Gilham	Independent Non-Executive Chairman	9.4yrs	UK£65.00k	0.43% £ 33.0k
Chris Henry Yates	Independent Non-Executive Director	5.7yrs	UK£35.00k	0.047% £ 3.6k
Thomas Lindsay	Independent Non-Executive Director	6yrs	UK£35.00k	0.18% £ 14.1k

5.7yrs

Average Tenure

54.5yo

Average Age

Experienced Board: GDR's board of directors are considered experienced (5.7 years average tenure).

genedrive Management

Management criteria checks 1/4

Key information

Recent management updates

genedrive plc, Annual General Meeting, Dec 29, 2023

genedrive plc Announces Chief Executive Officer Changes

genedrive plc, Annual General Meeting, Dec 29, 2022

High number of new directors

High number of new directors

genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial Officer

Recent updates

New major risk - Shareholder dilution

genedrive plc to Report First Half, 2024 Results on Mar 28, 2024

New major risk - Market cap size

genedrive plc, Annual General Meeting, Dec 29, 2023

New major risk - Share price stability

Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022)

New major risk - Market cap size

genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023

New minor risk - Financial data availability

genedrive plc Announces Chief Executive Officer Changes

Genedrive plc Achieves UKCA Marking Registration for its New Genedrive CYP2C19 System

Is genedrive (LON:GDR) In A Good Position To Invest In Growth?

genedrive plc, Annual General Meeting, Dec 29, 2022

Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021)

genedrive plc to Report Fiscal Year 2022 Results on Nov 21, 2022

genedrive plc Files US FDA Pre-Submission for the Genedrive® MT-RNR1 Product Range

Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel Treatment

Here's Why We're Watching genedrive's (LON:GDR) Cash Burn Situation

NICE to Evaluate the Genedrive MT-RNR1 Test

High number of new directors

Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory Agency

High number of new directors

Now 25% undervalued after recent price drop

First half 2022 earnings released

Genedrive plc Announces NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test

genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial Officer

Genedrive plc Provides Update on Point of Care Covid Test

genedrive plc to Report First Half, 2022 Results on Mar 29, 2022

genedrive plc Announces UK CTDA application for Point-of-Care Genedrive®?COV19-ID kit

Full year 2021 earnings released: UK£0.012 loss per share (vs UK£0.55 loss in FY 2020)

Insufficient new directors

We're A Little Worried About genedrive's (LON:GDR) Cash Burn Rate

Genedrive COVID-19 Point of Care device update

Here's Why genedrive (LON:GDR) Must Use Its Cash Wisely

First half 2021 earnings released: EPS UK£0.019 (vs UK£0.089 loss in 1H 2020)

New 90-day high: UK£1.49

genedrive plc Enters Distribution Agreement with Mountain Horse Solutions

genedrive plc Provides an Update on its Antibiotic Induced Hearing Loss Assay

New 90-day high: UK£0.98

genedrive plc Enters into Distribution Agreement with Beckman Coulter Life Sciences

Is genedrive's (LON:GDR) Share Price Gain Of 252% Well Earned?

genedrive plc to Report First Half, 2021 Results on Mar 25, 2021

New 90-day low: UK£0.42

genedrive plc, Annual General Meeting, Dec 30, 2020

New 90-day low: UK£0.49

Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation Study

Full year 2020 earnings released: UK£0.55 loss per share

Earnings beat expectations, revenue disappoints

Genedrive Announces HCV ID Kit Demonstrates High Clinical Accuracy in India Study

Full year 2020 earnings released: UK£0.55 loss per share

Earnings beat expectations, revenue disappoints

New 90-day low: UK£0.68

genedrive plc to Report Fiscal Year 2020 Results on Nov 17, 2020

genedrive plc Announces South African Approval

genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNA

New 90-day high: UK£1.34

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age